- |||||||||| fispemifene (HM-101) / Seelos Therap
Journal: Genome assembly of Medicago truncatula accession SA27063 provides insight into spring black stem and leaf spot disease resistance. (Pubmed Central) - Feb 28, 2024
The assembly enabled sequence-level analysis of rnpm1 and rnpm2 for gene content, synteny, and structural variation between SBS-resistant accession SA27063 (HM078) and SBS-susceptible accession A17 (HM101)...In rnpm2, we identified a frameshift mutation causing a loss-of-function in a glycosidase, as well as a missense and frameshift mutation altering an F-box family protein. This study generated a high-quality genome of HM078 and has identified promising candidates, that once validated, could be further studied in alfalfa to enhance disease resistance.
- |||||||||| fispemifene (HM-101) / Seelos Therap
[VIRTUAL] HMB101 - Double RNAseq in Pathogen-Host Interactions () - May 9, 2021 - Abstract #WMF2021WMF_3110;
Once the session is released, the presentation may be viewed on-demand through July 30, 2021.This session will discuss the new methods used for double RNA seq in the pathogen and host during their interactions. Upon completion of this Track Hub, the participant should be able to: Discuss RNAseq techniques Describe issues with troubleshooting RNAseq Examine host-pathogen interactions
- |||||||||| fispemifene (HM-101) / Seelos Therap
Enrollment closed, Trial primary completion date: Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men (clinicaltrials.gov) - Nov 14, 2015
P2, N=160, Active, not recruiting,
Upon completion of this Track Hub, the participant should be able to: Discuss RNAseq techniques Describe issues with troubleshooting RNAseq Examine host-pathogen interactions Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Oct 2015
|
